Orthofix Medical (OFIX)
Builds spine implants, biologics, bone-growth therapies and limb-reconstruction systems.
Something off on this page? Send us feedback.
Sells spine implants, biologics, bone-growth therapies, surgical navigation and limb-reconstruction systems through Global Spine and Global Limb Reconstruction. The portfolio is concentrated in spine, shaped by the SeaSpine merger, and still depends on reimbursement treatment for non-invasive bone-growth stimulators.
Offers spinal hardware, biologics, bone-growth therapies, specialized orthopedic solutions and enabling technologies, including the 7D FLASH navigation system. Global Spine is the main business line, while Global Limb Reconstruction serves deformity correction, limb lengthening, complex fracture management and limb preservation.
Runs from a Lewisville base with international roots and distribution across multiple countries. The SeaSpine combination broadened the spine platform with biologics, spinal hardware, bone-growth therapies, specialized orthopedic solutions and surgical navigation.
Current execution is focused on spinal fixation, deformity correction and commercialization of 7D navigation after the M6 artificial-disc lines were discontinued. Non-invasive bone-growth stimulators remain tied to FDA classification and CMS reimbursement treatment.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 10, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $18 | Target: $13 |
| Aug 6, 2026 | Barrington | Target | Target: $17 | Target: $14 |
| Aug 5, 2026 | Stifel Nicolaus | Target | Target: $18 | Target: $13 |
| Jul 6, 2026 | Barrington | Target | Target: $15 | Target: $17 |
| May 22, 2026 | Barrington | Target | Target: $18 | Target: $15 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $103.8M · Total debt $234.6M · Total assets $873.0M · Shareholders' equity $429.2M
- Revenue
- $210.9M
- Operating income
- −$8.1M
- Net income
- −$15.8M
No dividends on record.
| Institutions | 94.79% | 38.61M shares | |
|---|---|---|---|
| 142 holders · as of Jun 30, 2026 | |||
| Insiders | 3.71% | 1.51M shares | |
| 17 holders · as of Sep 3, 2026 | |||
| Other | 1.50% | 609.4K shares | |
| remainder | |||
40.73M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Engine Capital Management, LPInstitution | 11.23% | 4.58M | as of Jun 30, 2026 |
Juniper Investment Company, LLCInstitution | 10.91% | 4.44M | as of Jun 30, 2026 |
Rubric Capital Management LPInstitution | 9.14% | 3.72M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.17% | 3.33M | as of Jun 30, 2026 |
Paradigm Capital Management Inc/NYInstitution | 8.10% | 3.30M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 21, 2026 | Juniper Investment Company, LLC | 10 percent owner | −190,000 | $8.86 |
| Sep 18, 2026 | Juniper Investment Company, LLC | 10 percent owner | −120,000 | $8.74 |
| Sep 1, 2026 | Patrick Fisher | officer: President, Global Limb Recon | −150 | $9.39 |
| Aug 18, 2026 | Patrick Fisher | officer: President, Global Limb Recon | −1,295 | $10.09 |
| Aug 17, 2026 | Juniper Investment Company, LLC | 10 percent owner | −20,000 | $10.01 |
- Globus Medical
Broad spine, biologics, navigation, and limb reconstruction overlap
- Medtronic
Large-scale spine implants, biologics, and surgical-navigation rival
- Johnson & Johnson
DePuy Synthes overlap across spine, trauma, and limb reconstruction
- Enovis
Bone-stimulation and orthopedic-reconstruction overlap
- Bioventus
Focused bone-healing and orthobiologics overlap
- Alphatec
Spine-focused implants, biologics, and procedure-platform rival
- Stryker
Trauma, extremities, navigation, and orthobiologics overlap
- Smith & Nephew (ADR)
Orthopaedic trauma, extremities, and reconstruction overlap
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Orthofix Medical | $9.16 | +1.95% | $363.0M | — | — | 0.4 | +5.1% |
| Globus Medical | $74.68 | −0.68% | $10.14B | 19.3 | 14.6 | 3.2 | +5.9% |
| Medtronic | $90.15 | −0.69% | $116.19B | 22.4 | 15.0 | 3.1 | +13.7% |
| Johnson & Johnson | $268.54 | −0.24% | $648.72B | 31.2 | 22.6 | 6.6 | +6.6% |
| Enovis | $18.41 | +0.11% | $1.06B | — | 5.1 | 0.5 | +3.2% |
| Bioventus | $13.31 | −2.49% | $924.8M | 17.7 | 16.7 | 1.6 | +3.8% |
| Alphatec | $10.18 | −1.50% | $1.59B | — | 20.2 | 1.9 | +15.1% |
| Stryker | $273.57 | −0.55% | $105.45B | 28.5 | 17.1 | 4.1 | +9.4% |
| Smith & Nephew (ADR) | $26.83 | −2.45% | $11.55B | 18.8 | — | 1.8 | +4.6% |
| Median | 20.8 | 16.7 | 2.5 | +6.3% |